HAX’s VC-Founder Industry Hard Tech Matchup is now accepting applications. Register today!

John and the Quantumcyte team are deicated to using their technical skills to deliver unique capabilities to the clinical and diagnostic markets that accelerate clinical and diagnostics development. It turns out that approximately 25% of all cancer patient biopsies that are submitted for a clinically validated test fail to meet a critical specification callaed “tumor Purity”. Failure to meet this specification means that the patient will not benefit from the results of the test that could lead to a cure. The Quantumctye team has developed a technology that solves this problem. Core to our values is the need to deliver results from all biopsies.